Non-invasive Prenatal Testing (NIPT) Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

The Global Non-Invasive Prenatal Testing (NIPT) Market achieved a valuation of USD 4.03 Billion in 2022 and is poised for substantial growth throughout the forecast period, exhibiting a Compound Annual Growth Rate (CAGR) of 7.38% and expected to reach USD 6.16 Billion through 2028. Non-Invasive Prenatal Testing is a revolutionary prenatal screening method that entails analyzing a pregnant woman's blood sample to identify potential fetal abnormalities. This advanced technique, primarily employed to diagnose genetic disorders like Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), and Turner syndrome, involves scrutinizing DNA fragments within the maternal blood. Remarkably, this procedure eliminates the need for invasive processes such as chorionic villus sampling (CVS), providing a safer alternative and can be administered after the ninth week of pregnancy.

Key Market Drivers

Increasing Emphasis on Early Detection and Prevention

A rising focus on early detection and prevention has significantly fueled the demand for Non-Invasive Prenatal Testing (NIPT). This pioneering screening technique enables the identification of specific genetic abnormalities in a developing fetus through a straightforward maternal blood test, diverging from conventional invasive approaches like amniocentesis or chorionic villus sampling (CVS), which carry the risk of miscarriage. NIPT stands out as a safer alternative, offering reliable early genetic screening.

Availability of Advanced Screening Technologies

Advancements in genome sequencing technologies, particularly Next-Generation Sequencing (NGS), have streamlined diagnosis processes with reduced turnaround time. These advances facilitate the development of non-invasive diagnostics, enabling accurate detection of various genetic disorders. This, coupled with the growth of NGS-based NIPT tests, strengthens the industry's capability to provide precise results while maintaining competitiveness.

Healthcare Shift in Reimbursement Policies Towards Genetic Coverage

Alterations in reimbursement policies play a pivotal role in enhancing the affordability and accessibility of medical services. Adjustments that render NIPT financially feasible for patients can lead to heightened adoption rates. The non-invasive nature and accuracy of NIPT, as compared to traditional methods, position it as an appealing option for expectant parents. When NIPT costs are covered by insurance, it becomes a viable choice for a broader spectrum of individuals.

Increasing Prevalence of Genetic and Congenital Disorders

The escalating prevalence of genetic and congenital disorders significantly contributes to the demand for NIPT. As awareness grows and the impact on families becomes apparent, prospective parents seek means to ensure the well-being of their unborn children. NIPT, as a non-invasive and accurate method for early detection, emerges as a preferred choice for those at higher risk.

Key Market Challenges

Limitations of NIPT

Despite its high accuracy, there remains a possibility of false-positive or false-negative results in NIPT. This uncertainty might create hesitancy among patients in fully relying on NIPT for diagnostic decisions. Additionally, NIPT is a screening test, necessitating follow-up invasive diagnostics to confirm positive results.

Alternative Screening and Testing Methods

Traditional serum screening tests, sequential screening, and invasive methods like amniocentesis or CVS might still be favored due to familiarity, recommendations, or perceptions about accuracy. Awareness gaps about the benefits of NIPT might divert patients towards alternatives.

Key Market Trends

Availability of Direct-to-Consumer Tests

The availability of Direct-to-Consumer (DTC) NIPT tests holds the potential to substantially elevate demand. DTC testing empowers individuals to access genetic testing services without medical intermediaries. While concerns exist, DTC testing can augment awareness, accessibility, and utilization of NIPT.

Focus on Pre-Implantation Genetic Diagnosis

The combination of Pre-Implantation Genetic Diagnosis (PGD) and NIPT presents comprehensive genetic health assessment both pre- and post-implantation. NIPT can validate PGD results and provide assurance to parents regarding genetic health.

Segmental Insights

Product Type Insights

Within the product type segment, trisomy conditions dominate, and NIPT emerges as an effective method for detecting trisomy 21, 18, and 13. The method's exceptional sensitivity and specificity in pregnancies resulting from in-vitro fertilization (IVF) further bolster its significance.

End User Insights

Diagnostic laboratories lead the end-user category due to increased preference for NIPT among both patients and healthcare professionals. The surge in test volumes and initiatives for safe prenatal testing contribute to this segment's growth.

Regional Insights

In 2022, North America holds the largest market share, propelled by demand for genetic testing, advanced research framework, and reimbursement support. Europe follows due to high prevalence of Down syndrome and increased childbearing at advanced maternal ages. Asia Pacific is projected for rapid growth due to a surge in pregnancies with genetic conditions and governmental initiatives.

Key Market Players

• YOURGENE HEALTH Plc
• Illumina, Inc.
• Natera, Inc.
• F.Hoffman La Roche Ltd.
• Perkin Elmer Inc.
• Laboratory Corporation of America Holdings
• Eurofins LifeCodex GmbH
• Progenity, Inc.
• Genesis Genetics
• Quest Diagnostics Incorporated

Report Scope:

In this report, the Global Non-invasive Prenatal Testing (NIPT) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-invasive Prenatal Testing (NIPT) Market, By Product Type:

• Consumables
• Instruments

Non-invasive Prenatal Testing (NIPT) Market, By Test Type:

• Materni 21
• Harmony
• Panaroma
• Verifi
• NIFTY
• Others

Non-invasive Prenatal Testing (NIPT) Market, By Method:

• Ultrasound Detection
• Biochemical Screening Testing
• Cell-Free DNA Maternal Plasma Tests
• Fetal Cells in Maternal Blood Tests
• Others

Non-invasive Prenatal Testing (NIPT) Market, By Application:

• Trisomy
• Microdeletion Syndrome
• Others

Non-invasive Prenatal Testing (NIPT) Market, By End User:

• Diagnostic Laboratories
• Hospitals
• Others

Non-invasive Prenatal Testing (NIPT) Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-invasive Prenatal Testing (NIPT) Market.

Available Customizations:

Global Non-invasive Prenatal Testing (NIPT) market report with the given market data, the publisher offers customizations according to a company's specific needs.


This product will be delivered within 1-3 business days.